List of Carospir drug patents

Carospir is owned by Cmp Dev Llc.

Carospir contains Spironolactone.

Carospir has a total of 8 drug patents out of which 0 drug patents have expired.

Carospir was authorised for market use on 04 August, 2017.

Carospir is available in suspension;oral dosage forms.

Carospir can be used as carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; carospir is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents; carospir is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction, carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure.

The generics of Carospir are possible to be released after 28 October, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9757394 CMP DEV LLC Spironolactone aqueous formulations
Oct, 2036

(13 years from now)

US10493083 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US10888570 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US10660907 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US10624906 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US11395828 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US11389461 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US11491166 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

Drugs and Companies using SPIRONOLACTONE ingredient

Market Authorisation Date: 04 August, 2017

Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; Carospir is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents; Carospir is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction

Dosage: SUSPENSION;ORAL

How can I launch a generic of CAROSPIR before it's patent expiration?
More Information on Dosage

CAROSPIR family patents

12

United States

1

Canada

1

Morocco

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic